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Abstract 
Genetic variation across the HLA is known to influence renal-transplant outcome. However, the 
impact of genetic variation beyond the HLA is less clear. We tested the association of common 
genetic variation and clinical characteristics, from both the donor and recipient, with post-transplant 
eGFR at different time-points, out to 5-years post-transplantation. 
We conducted GWAS meta-analyses across 10,844 donors and recipients from five European 
ancestry cohorts. We also analysed the impact of polygenic risk scores (PRS), calculated using 
genetic variants associated with non-transplant eGFR, on post-transplant eGFR.  
PRS calculated using the recipient genotype alone, as well as combined donor and recipient 
genotypes were significantly associated with eGFR at 1-year post-transplant. 32% of the variability in 
eGFR at 1-year post-transplant was explained by our model containing clinical covariates (including 
weights for death/graft-failure), principal components and combined donor-recipient PRS, with 0.3% 
contributed by the PRS. No individual genetic variant was significantly associated with eGFR post-
transplant in the GWAS.  
This is the first study to examine PRS, composed of variants that impact kidney function in the 
general population, in a post-transplant context. Despite PRS being a significant predictor of eGFR 
post-transplant, the effect size of common genetic factors is limited compared to clinical variables. 
 
1. Introduction 
Since the discovery of the HLA in the 1950s, it has been clear that genetic factors are important in 
kidney transplant outcomes
1
. A number of studies have examined candidate genes or variants 
beyond the HLA and their impact on graft function
2-4
, however, few have been replicated
5
. To date, 
only a small number of genome-wide association studies (GWAS) have analysed medium/long-term 
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allograft outcome
6-8
. A study from 2013 identified recipient genotype loci on chromosomes 14 and 
18 which significantly associated with 5 years serum creatinine and long-term graft survival
6
. 
However, this study was limited by its sample size (n=326) and an independent effort failed to 
replicate the findings
9
. This highlights the need for larger, robust GWAS of allograft outcome to 
determine the extent to which common variation affects the outcome of kidney transplantation.  
Kidney transplants are a relatively rare phenotype and collaborative efforts such as the UK and 
Ireland Renal Transplant Consortium (UKIRTC
7
) and International Genetics & Translational Research 
in Transplantation Network (iGeneTRAiN
10
) facilitate well-powered studies of transplant related 
phenotypes. Recently the UKIRTC published a GWAS of kidney transplant outcomes which examined 
graft survival and acute rejection in the first twelve months post-transplant, in a deceased donor 
cohort of 2,094 transplant pairs
7
. Although much better powered than earlier efforts, no significant 
associations were found beyond the previously known effect of the HLA. A GWAS involving pooled 
DNA from 4,127 renal transplant recipients identified signals of association with T-cell mediated 
acute rejection at the PTPRO and CCDC67 loci. The finding was replicated, but not as part of an 
independent study
8
. Neither the PTPRO or CCDC67 signal replicated in the UKIRTC GWAS of acute 
rejection, however the definition of acute rejection in the UKIRTC study
11
 was not specific to T-cell 
mediated rejection which may explain the discordance. Here, we hypothesise that a continuous 
variable of outcome (i.e. eGFR) would provide additional power to detect the impact of genetic 
variation on markers of graft outcome. 
In non-transplant populations, there has been a number of large well-powered GWAS that have 
identified genetic variants that associate robustly with kidney function
12-15
, the largest of which (n= 
133,814) was carried out by Pattaro et al 
13
. However, despite the identification of a number of risk 
loci, univariate effect sizes were small (OR of 0.93 to 1.06 for the 23 novel loci identified).  
Common genetic variants typically have small effects on complex human traits, and thus are usually 
not of clinical relevance. Polygenic risk scores (PRS) quantify the cumulative effects of a number of 
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loci, which may individually have a small predictive ability. By doing so, PRS’s may be more clinically 
relevant than looking at common genetic variants independently. One study, by Gorski et al
12
, used 
summary statistics from their GWAS of estimated glomerular filtration rate (eGFR) to create a 
polygenic risk score (PRS) which was then tested against eGFR in an independent cohort of 1,017 
individuals. They found the PRS to explain 2.2% of the trait variance compared to 1.3% when just 
considering genome-wide significant loci.  
In this study, we set out to test the hypothesis that common variation from donor or recipient 
genotype is associated with short and medium term allograft kidney function, using 1-year, 5-year 
and ∆ (change between 1 and 5 year) eGFR as measures of kidney function. Involving 10,844 
transplant donors and recipients, and delivered through the iGeneTRAiN consortium, this study is 
the largest GWAS of allograft function to date. In addition to studying the association of individual 
SNPs with eGFR, we also set out to test the hypothesis that higher polygenic load for increased eGFR 
in the donor, recipient and combined (donor and recipient) genomes is associated with increased 
graft function. To do this, we tested if PRS estimated using alleles from a GWAS of kidney function 
(using eGFR as a proxy) in a non-transplant population
13
 is predictive of kidney function in a number 
of renal transplant cohorts. 
 
2. Materials and Methods 
2.1. Cohorts 
We assembled five cohorts via the iGeneTRAiN consortium
10
. They are 1) ‘Transplant Lines’ (the 
Netherlands), 2) the Vienna/Prague cohort (Austria), 3) the Deterioration of Kidney Allograft 
Function Genomics (DeKAF) cohort (United States, NCT00270712), 4) the Genomics of Kidney 
Transplantation (GEN03) cohort (United States, NCT01714440) and 5) the United Kingdom and 
Ireland Renal Transplant Consortium (UKIRTC) cohort. See Table 1 for cohort descriptions and 
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supplementary methods for genotyping and imputation information.  The appropriate ethics 
committees at each site approved the protocol for this study.   
Notably, GEN03 and DeKAF Genomics cohorts were entirely living donor transplants whereas 
UKIRTC, TransplantLines and Vienna/Prague cohort was predominantly deceased donor transplants. 
In TransplantLines, the year of transplant ranged from 1993-2008. In the UKIRTC, the year of 
transplant ranged from 1981-2007. In DEKAF Genomics, transplants were performed between 2005-
2011 and in the GEN03 study from 2012-2016. In the Vienna/Prague cohort, the year of transplant 
ranged from 2005 to 2015. 
 
2.2. Phenotype  
We set out to analyse three phenotypes in each of these cohorts: eGFR at one-year post-renal 
transplant, eGFR at five years post-transplant and the change in eGFR from one to five years (Δ) 
post-transplant (see supplementary methods for details on calculating eGFR).   
The following inclusion/exclusion criteria were applied: Participants must 1) be of European 
ancestry, 2) have donated/received a renal transplant and 3) be unrelated to level of 3
rd
 degree 
relative.  
To identify individuals of European ancestry, all patient cohorts were merged with samples from the 
Human Genome Diversity project (representing seven different global populations) or the 1000 
Genomes Project and analysed using principal components analysis (PCA). Principal component (PC) 
1 was plotted against PC2 and individuals in the patient cohorts that did not overlap with the 
European individuals in the HGDP were removed. To identify individuals unrelated beyond 3
rd
 
degree, we used PLINK’s --genome function to calculate identity-by-descent (PIHAT) scores16. One 
individual from each pair of related individuals (i.e. 3
rd
 degree, or closer relatives) was excluded from 
the analysis
16
.  
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2.3. Clinical analyses 
We first assessed a number of available clinical predictors of allograft function (see supplementary 
table 1 for list and definitions of clinical variables tested). These clinical variables were tested on a 
dataset of over 1,400 renal transplant recipients from TransplantLines and Dublin (subset of UKIRTC 
cohort). Significant clinical variables identified in the univariate linear regression analysis (see Table 
2) were then tested in a stepwise regression model (see Supplementary Tables 2-7). Collinear 
variables were removed and the remaining clinical variables were included as covariates in our 
genetic analyses. See supplementary methods for further details. 
 
2.4. Genome-wide association study 
Genome-wide association studies were carried out at each site independently for each available 
outcome variable (log10 1-year eGFR, log10 5-year eGFR and ∆ eGFR) with PCs (to correct for 
population-specific allelic differences), and available clinical variables with weights for death and 
failure in the log10 1-year eGFR and log10 5-year eGFR GWAS included as covariates (see 
supplementary methods section). GWAS were conducted separately for donor and recipient 
genotypes. See supplementary methods section 4 for further details.  
The results from each site were then combined using a meta-analysis approach (see supplementary 
methods for further details). The meta-analysis approach utilised in this study has previously been 
applied in a number of other genome-wide analyses of common genetic variation including analyses 
of kidney function
13,17-19
. Genome-wide level of significance was set at 5x10
-8
 for the GWAS meta-
analysis. 
Retrospective power calculations were carried out using a combination of R’s pchisq and qchisq 
functions. In the recipient full model (significant clinical covariates (including weights for 
death/failure for the log10 1-year eGFR and log10 5-year eGFR analyses – see supplementary 
methods), principal components and given genetic variant) we had 80% power to detect a variant 
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which explains 0.75%, 1.87% and 2.20% of outcome variance in the one-year, five-year and Δ 
recipient analysis respectively. In the donor full model GWAS, we had 80% power to detect a variant 
which explains 1.12%, 2.13% and 2.49% of outcome variance in the one-year, five-year and Δ donor 
analysis respectively.  
In the recipient baseline model (just PCs, failure and death as covariates), we had 80% power to 
detect a genetic variant which explains 0.67%, 1.39% and 1.78% of outcome variance in the one-
year, five-year and Δ recipient analysis respectively. In the donor baseline GWAS, we had 80% power 
to detect a variant which explains 0.98%, 1.58% and 2.01% of outcome variance in the one-year, 
five-year and Δ donor analysis respectively.  
 
2.5. Polygenic risk analysis  
For the PRS analysis, we employed the same clinical covariates and outcome measures as the GWAS 
analysis. We defined PRS as the sum of the alleles associated with a given trait weighted by the 
effect size of that allele as determined by a previous GWAS
20
. PRSs were calculated using results of a 
previous GWAS of eGFR in a non-transplant population
13
. We calculated the PRS at multiple p-value 
thresholds to enable us to examine at different sets of SNPs (for example, is the top 1,000 or top 
10,000 most significant SNPs associated with eGFR in the general population a better predictor of 
eGFR post-transplant). See supplementary methods for further details on how we calculated these 
scores. PRSs were then tested as predictors of each outcome variable correcting for available 
significant clinical covariates (as discussed previously) and PCs using in a linear regression model (see 
supplementary methods for further details). Linear regressions were carried out separately at each 
site and then combined using a meta-analysis approach in line with previously published meta-
analyses of PRS 
21
. See supplementary methods for further details. 
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3. Results 
This study involved 10,844 transplant donors and recipients recruited from UKIRTC (n=4,108), 
TransplantLines (n=1,806), GEN03 (n=1,039), DeKAF (n=2,666) and Vienna/Prague (n=1,225). The 
mean age of recipients and other clinical variables are reported in Table 1. Subjects had a mean 
eGFR of 52.43ml/min at 1 year and 51.39ml/min at 5 years post-transplant. The mean Δ eGFR was -
1.01ml/min. Distributions of eGFR in each of the five cohorts can be seen in Supplementary Figures 1 
to 4.  
 
3.1. Clinical analysis  
Clinical covariates were tested in a combined cohort comprising over 1,400 renal transplant 
recipients from TransplantLines and the Dublin subset of the UKIRTC (see supplementary methods 
for further details). After correcting for multiple testing and collinearity (see Supplementary Table 2-
7), we identified donor age, donor type, donor sex, recipient age, delayed graft function and acute 
rejection as significant predictors of log10eGFR at 1-year. These variables explained 22% of the 
outcome variance.  
Donor age, mycophenolate mofetil exposure, delayed graft function, acute rejection and donor type 
were identified as significant predictors of log10eGFR at 5-years. These variables explained 21% of 
the variance in eGFR at 5 years post-transplant.  
Recipient age at time of transplantation, mycophenolate mofetil exposure and acute rejection were 
identified as significant predictors of ∆ eGFR. These variables explained 4% of the variance in delta 
eGFR. These clinical predictors of eGFR were brought forward for the following GWAS and polygenic 
risk score analyses. 
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3.2. Genome-wide association study 
To test the hypothesis that, in a univariate model, common donor or recipient genotype is 
associated with graft function, imputed genotype data was tested against log10 eGFR at 1-year and 5-
years post-transplant and ∆ eGFR between 1 and 5 years taking a GWAS approach.  
No genome-wide significant signals were detected in the donor or recipient GWAS in either the 
baseline or full model for log10 eGFR at 1-year or 5-year post-transplant or ∆ eGFR (see Figure 1 and 
Supplementary Figures 5-16). The top ten most significant variants for each GWAS are described in 
Supplementary Tables 8-13. The genomic inflation for each of the GWASs was minimal and the 
GWASs appeared to behave normally when the expected versus observed p-values were plotted 
(see Supplementary Figures 5-16).  
 
3.3. Polygenic risk analysis  
Having assessed the donor and recipient genotype in a univariate model, we next examined 
common genetic variation in a multivariate polygenic risk model. Using linear regression models, we 
tested the hypothesis that a polygenic load for increased eGFR (calculated using alleles from non-
transplant populations, see methods section 2.5) in the kidney donor, recipient or combined (donor 
and recipient) genotype, is associated with increased post-transplant eGFR (see Table 3). The PRS at 
pT 0.0001 calculated using the recipient genotype and the combined donor-recipient genotype 
significantly predicted log10 eGFR at 1-year post-transplant (see Figure 2 and 3). These figures 
illustrate that the effect size was consistent across sites with an increased PRS leading to a higher 
eGFR post-transplant - i.e. increased number of alleles that predict higher eGFR in non-transplant 
populations correlates with higher eGFR post-transplant. 
The amount of variance explained by the full model (significant clinical covariates including weights 
for death/failure, principal components and polygenic risk score at pT 0.0001) for the combined 
donor-recipient PRS was 32% with 0.3% contributed by the PRS.  The amount of variance explained 
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by the full model for the recipient PRS was 30% with 0.2% contributed by the PRS (see 
Supplementary Table 14).  Notably, approximately 9% of the variance explained by clinical variables 
is attributed to the death/failure weights (see Supplementary Table 14).   
None of the PRS (at any pT) significantly predicted log10 eGFR 5 years or ∆ eGFR when calculated 
using the donor, recipient, or combined (sum of the donor and recipient alleles) genotype. Also, 
none of the PRS calculated using solely the donor alleles were significant predictors of any of the 
outcomes tested. Low heterogeneity was found across sites (see Table 3).   
 
4. Discussion 
In this study, we set out to test the impact of clinical variables and common genetic variation from 
both the donor and recipient on eGFR post-transplant using both univariate and polygenic methods. 
Although both clinical variables and polygenic risk scores were found to be predictive of eGFR post-
transplant, clinical variables explained several orders of magnitude more of trait variance. 
We identified a number of significant clinical predictors of eGFR at 1 and 5 years including donor 
age, donor type (living/deceased), donor sex, recipient age, delayed graft function, acute rejection 
and  mycophenolate mofetil exposure. Collectively, these variables explained over 20% of the 
variance in eGFR at 1 and 5 years post-transplant. We also found that recipient age at time of 
transplantation, mycophenolate mofetil exposure and acute rejection predicted change in renal 
function over the first 5 years post-transplant. These findings and the direction of effect of these 
variables are in line with the literature and have all been previously implicated in eGFR post-
transplant
22-24
. Notably, mismatches at HLA A, B and DR and the total number of mismatches across 
these three loci (calculated using serological testing) were not found to be significant in our clinical 
analysis (see Table 2). This likely due to advancements in immunosuppression as well as most donors 
and recipients being matched based on preferential HLA typing, which in combination are masking 
the effects of the HLA. 
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We did not find any donor or recipient SNP that associated (post-correction for multiple testing) with 
eGFR at 1 year, 5 years or ∆ eGFR post-renal transplantation.  However, in the top SNPs from a 
number of the GWAS there were some interesting and potentially biologically relevant signals – 
although we stress these were not significant and so their role in graft function remains uncertain. 
For example, in our donor log10 5-year eGFR full model GWAS, the most significant SNP was found in 
the fifth intron of the Cub and Sushi Multiple domains 1 gene (CSMD1). CSMD1 has been implicated 
in a variety of diseases including schizophrenia and colorectal cancer
25,26. CSMD1 has also been 
proposed as a regulator of the complement pathway – a pathway essential for inflammation and 
immune regulation
27
.  Over the past decade, evidence has emerged which implicates the 
complement pathway in allograft ischemia-reperfusion as well as alloimmunity that results in graft 
injury thereby affecting the life-span of the graft 
28
. Further work is required to decipher if common 
variants in this gene play a role in allograft function.  
For our donor GWAS of delta eGFR, in both the baseline and full models, the most significantly 
associated variant with delta eGFR was rs136237 (full model p= 7.89x10
-7
, baseline model p = 
7.04x10
-7
), a SNP in the third intron of the oxysterol-binding protein 2 gene (OSBP2). This gene 
encodes a protein that binds some oxygenated forms of cholesterol called oxysterols and inhibits 
their functions 
29
. Oxysterols are involved in a vast range of important biological processes including 
apoptosis and platelet aggregation 
30
. OSBP2 is expressed at low levels in the kidney31,32. Further 
work is required to validate this finding. 
Despite some interesting signals towards the tail of the distribution, none reached statistical 
significance and so our findings indicate that no single common genetic variant, in either the donor 
or recipient genome, explains a clinically relevant proportion (>2%) of the variation in eGFR post-
kidney transplantation. It is probable that there are SNPs explaining a smaller proportion of eGFR 
post-transplant, but we were underpowered to detect these under a univariate model. This study 
focused specifically on common genetic variation, it is possible that rare variation in the donor 
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and/or recipient genotype is influencing allograft function, but further work is required to clarify 
this. 
We demonstrated that both recipient PRS and our combined PRS model significantly associated with 
log10 eGFR at 1-year post-transplant. We found that the recipient and combined PRS at pT 0.0001 
was significantly associated with log10 1-year eGFR, indicating that common sub-genome-wide 
significance threshold (5x10
-8
) genetic variants influence graft outcome. This PRS was not found to 
associate with ∆ eGFR or log10 5-year GFR. This may indicate that the genetic variation that 
influences graft outcome is different for short-term outcome than that for medium-term or long-
term graft function. This is consistent with our clinical findings, where concordance between the 
clinical variables that predict 1-year eGFR and 5-year eGFR is incomplete, indicating that different 
factors affect early stage vs medium stage graft function. However, we had more samples in our 1-
year eGFR, than in our 5-year eGFR analysis and so potentially with larger numbers in the 5-year 
analysis this PRS may become significant as the same effect size and direction was seen.  
Approximately 30% of the variance in log10 1-year eGFR was explained by our full model (clinical 
covariates including weights for death/graft-failure, PC and PRS) in both the recipient PRS and 
combined PRS analysis. The majority of this variation was explained by the clinical covariates and 
less than ~ 0.3% of the variance is explained by either PRS. Interestingly, Gorski et al
12
 found that a 
PRS based on eGFR associated variants calculated at the same p-value threshold (pT 0.0001) 
explained 1.7% of the outcome variance in non-transplant populations indicating that although the 
genetic basis for GFR post-transplant overlaps with that in non-transplant individuals, there are 
differences. However, our PRS was based off a different set of GWAS results
13
 than that in Gorski et 
al and their paper used a different method for calculating the PRS which may account for differences 
between the variance explained. The PRS, albeit not clinically relevant, does highlight that the 
recipient genotype, as well as the donor genotype, is associated with early-stage graft function. 
Notably, the donor genotype is only significant in the context of the recipient genotype (i.e. in our 
combined model).  
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Our study had a number of limitations. Firstly, although we had relatively comprehensive phenotypic 
data and corrected for clinical covariates, we likely did not have sufficient data to account for all 
clinical heterogeneity within and between our cohorts. In particular, our cohorts had different eras 
of transplantations and therefore different immunosuppression protocols which may have led to 
additional heterogeneity between cohorts. Potentially, through analysis of more similar cohorts we 
may have had more significant findings.  However, in the PRS analyses, we did test for heterogeneity 
between our cohorts and found it to be minimal and any SNPs with high levels of heterogeneity in 
our GWAS were removed.  
Secondly, these meta-analyses were carried out on European ancestry populations and therefore 
further work is needed to investigate single variant and polygenic effects in other non-European 
populations. 
In conclusion, we found that polygenic effects of common genetics variants influence short-term 
allograft function but did not find any significant associations in our univariate model. This study is 
the first of its kind to look at the impact of polygenic effects of variants that impact kidney function 
in the general population in a post-transplant context. Our finding suggests that although common 
genetic variation does impact graft outcome, the effect size is limited compared to clinical variables. 
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Figure legends 
 
Figure 1. Manhattan plots of recipient and donor log10 1-year, log10 5-year and Δ eGFR – full model  
The red line indicates the genome-wide significance threshold (5x10
-8
), the blue line indicates 
suggestive significance threshold (1x10
-5
).  A = recipient log10 1-year eGFR – full model (λ (genomic 
inflation factor) = 1.01). The top SNP was an intergenic variant on chr17p13.3. N SNPs = 3,673,881. 
B= donor log10 1-year eGFR – full model (λ = 1.01). N SNPs = 3,641,041. The most significant SNP was 
found in an intergenic region on chr12p13.1. C= recipient log10 5-year eGFR – full model (λ = 0.99). 
The top SNP was an intergenic variant on chr17q22. N SNPs = 3,924,633. D= donor log10 5-year eGFR 
– full model (λ = 1.01). N SNPs = 3,938,549. The most significant SNP was found on chromosome 8 in 
an intron of CSMD1. E= recipient Δ eGFR – full model (λ = 1.01). The top SNP was found in the gene 
ZNF551 on chromosome 19. N SNPs = 3,915,961.  F= donor delta eGFR – full model (λ = 1.01). N SNPs 
= 3,927,634. The most significant SNP was found on chromosome 22 in an intron of OSBP2.  
 
Figure 2. Recipient PRS at pT 0.0001 as a predictor of log10 eGFR at 1-year post-transplant 
Site = study cohort. TxLines= TransplantLines. Vienna = Vienna/Prague cohort. Weight= proportion of 
data the given site contributed to overall model; coef [95% CI] = effect size with lower and upper 95% 
confidence intervals. PRS_pT_0.0001 = normalized recipient PRS of eGFR at p-value threshold 0.0001, 
RE model = Random-effects model. Model was adjusted for significant clinical covariates and the first 
eight principal components at each site (see section 3.1).  
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Figure 3. Combined PRS at pT 0.0001 as a predictor of log10 eGFR at 1-year post-transplant 
Site = study cohort. TxLines= TransplantLines. Vienna = Vienna/Prague cohort. Weight= proportion of 
data the given site contributed to overall model; coef [95% CI] = effect size with lower and upper 95% 
confidence intervals. Combo_PRS_pT_0.0001 = normalized combined PRS of eGFR at p-value 
threshold 0.0001. RE model = Random-effects model. The model was adjusted for significant clinical 
covariates and the first eight principal components at each site (see section 3.1).  
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Tables 
Table 1. Descriptive statistics for each cohort of significant clinical predictors and eGFR measures 
The above table provides descriptive statistics for the UK and Ireland Renal Transplant consortium 
cohort (UKIRTC), TransplantLines cohort (TxLines), GEN03, DeKAF and Vienna/Prague cohort. N = 
number of individuals, %  = Percentage, % with failure by year 1/5 = Percentage with a failure event 
within 1/5 years post-transplant, % with death by year 1/5= Percentage who died within 1/5 years 
post-transplant, % on mycophenolate mofetil = percentage of patients who received mycophenolate 
mofetil at the start of their transplant (intention to treat), % living = percentage of living donors, 
stdev = standard deviation, min = minimum value observed, max = maximum value observed. 
Delayed graft function status was unavailable for the UKIRTC cohort. Acute rejection status for the 
 UKIRTC TxLines GEN03 DeKAF 
Vienna/ 
Prague 
Recipients 
N   2233 983 673 1864 616 
Range of year of transplant 
1981-
2007 
1993-
2008 
2012-
2016 
2005-
2011 
2005-2015 
% male 64% 57% 62% 63% 63% 
Average length of follow-up post-
transplant - years 
8.47 (4) 9.77 (5) 
1.90 
(0.8) 
2.25 (1) 4.75(3) 
Average age at transplant 
46.32 
(13) 
48.26 
(13) 
50.25 
(15) 
50.46 
(14) 
52 (14) 
% with failure by year 1 1% 4% 0% 0% 5% 
% with death by year 1 0.3% 2% 0% 1% 3% 
% with failure by year 5 8% 10% 1% 3% 10% 
% with death by year 5 4% 8% 1% 3% 8% 
% on mycophenolate mofetil 37%* 72% 100% 95% 99% 
% with delayed graft function NA 30% 6% 7% 30% 
% Acute rejection episode by year 1 20.57%* 30% 15% 14% 36% 
% Acute rejection episode by year 5 NA 33% 16% 18% 40% 
Donors 
N 1875 823 366 802 609 
% male 57% 52% 43% 41% 56% 
Average age 43.1 (16) 
43.02 
(15) 
45.50 
(12) 
44.31 
(11) 
50 (14) 
% Living 0% 17% 100% 100% 15% 
eGFR at 1 
year 
N observations 1905 937 673 1864 556 
Mean 48.1 45.6 61.9 58.1 52.5 
Median 47.1 44.6 59.2 55.9 50.8 
Max 120.5 108.7 201.2 217.6 109.8 
Min 4.5 2.5 15.0 4.0 2.0 
Stdev 17.8 18.8 21.8 20.8 18.8 
eGFR at 5 
year 
N observations 1700 906 NA NA 315 
Mean 46.4 46.2 NA NA 51.5 
Median 44.9 45.9 NA NA 50.8 
Max 122 181 NA NA 105 
Min 4.1 2.5 NA NA 9.4 
Stdev 19.4 22.5 NA NA 19.9 
∆ eGFR 
N observations 1283 719 NA NA 296 
Mean -1.8 2.0 NA NA -2.5 
Median -1.8 2.7 NA NA -2.9 
Max 65.6 73.3 NA NA 45.9 
Min -57.3 -60.4 NA NA -45.4 
Stdev 13.4 16.1 NA NA 12.3 
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UKIRTC cohort was only available for the first twelve months post-transplant. ∆ eGFR and 5-year 
eGFR were unavailable for the GEN03 and DeKAF cohorts. 
* A large number of the UKIRTC patients had missing information for MMF and AR status and so 
these percentages were calculated from those who had yes/no status for MMF and individuals with 
missingness were excluded.  MMF % was calculated as follows:  1045 N – not exposed to MMF, 604 – 
were exposed, 584 = missing. (604/ (1045 + 604))*100/1 = 36.62%. For acute rejection at 1 year, 
1093 – did not experience an AR episode in the first twelve months, 283 did have an AR episode and 
857 were missing. AR % was calculated as follows: (283 / (1093 + 283)) * 100/1= 20.57%.  
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Coef. = regression coefficient; SE=standard error; Pbon = Bonferroni corrected p value (unadjusted p value*20); N = number of individuals tested 
(i.e. who had the measure available); Site = cohort associated with given individual where Dublin =one and TransplantLines =zero. Graft failure 
and death with a functioning graft were adjusted for in the log10 1-year and 5 year eGFR analyses. Acute Rejection = acute rejection within 1 year 
post-transplant for log10 1-year eGFR analysis and within 5 years for ∆ eGFR and log10 5-year eGFR analysis. Azathioprine = azathioprine - 
intention to treat at start of transplant. Cold Ischemic Time = cold ischemic time in minutes. CMV = cytomegalovirus infection in recipient post-
transplant. Corticosteroids = intention to treat at start of transplant. Cyclosporin = intention to treat at start of transplant. Delayed graft function 
= yes/no. Donor age = donor age at time of transplant. Donor sex = male = 0, female = 1. Donor Type = Living/deceased = living = 1, deceased = 0. 
HLA-mismatch A = Number of HLA mismatches between donor and recipient at A locus. HLA-mismatch B = Number of HLA mismatches between 
donor and recipient at B locus. HLA-mismatch DR = Number of HLA mismatches between donor and recipient at DR locus. Mycophenolate = 
Mycophenolate - intention to treat at start of transplant. Recipient age = recipient age at time of transplant. Recipient sex = recipient sex - 
male=0, female=1. Sirolimus = Sirolimus - intention to treat at start of transplant. Site = Dublin/TransplantLines, Dublin = 1, TransplantLines = 0. 
Tacrolimus  
= Tacrolimus - intention to treat at start of transplant. Total MM = Total number of HLA mismatches across A, B and DR locus.  
Clinical Variable 
Log 1-year eGFR Log 5-year eGFR ∆ eGFR 
Coef. SE Pbon N Coef. SE Pbon N Coef. SE Pbon N 
Acute Rejection -0.07 0.01 1.53x10
-8
 1407 -0.09 0.01 3.48x10
-11
 1399 -4.57 0.99 8.08x10
-5
 1108 
Azathioprine 0.02 0.01 1 1406 -0.01 0.01 1 1399 -3.61 1.09 0.02 1108 
Cold Ischemic Time -0.00004 0.00001 0.001 1400 -0.00004 0.00001 0.0009 1392 -0.001 0.001 1 1108 
CMV -0.04 0.01 0.0004 1407 -0.04 0.01 0.06 1340 -1.54 0.97 1 1108 
Corticosteroids 0.09 0.03 0.02 1402 0.08 0.03 0.24 1399 -3.89 2.65 1 1108 
Cyclosporin 0.04 0.02 0.48 1355 0.03 0.02 1 1399 1.34 1.48 1 1108 
Delayed graft function -0.09 0.01 2.42x10
-13
 1407 -0.09 0.01 1.39x10
-8
 1398 0.86 1.15 1 1103 
Donor age -0.004 0.0003 3.84x10
-30
 1407 -0.004 0.0004 1.41x10
-20
 1399 -0.02 0.03 1 1063 
Donor sex -0.04 0.01 0.001 1407 -0.03 0.01 0.08 1399 0.47 0.93 1 1108 
Donor Type -0.07 0.01 3.54x10
-7
 1407 -0.05 0.02 0.006 1399 -0.39 1.16 1 937 
HLA-mismatch A 0.00 0.01 1 1407 -0.01 0.01 1 1196 -1.11 0.78 1 1108 
HLA-mismatch B -0.01 0.01 1 1407 0.00 0.01 1 1196 0.40 0.74 1 936 
HLA-mismatch DR 0.01 0.01 1 1407 0.003 0.01 1 1195 -0.72 0.84 1 937 
Mycophenolate 0.02 0.01 1 1196 0.05 0.01 0.003 1399 3.52 0.94 0.004 1107 
Recipient age -0.003 0.0004 1.3x10
-9
 1195 -0.0005 0.0004 1 1399 0.17 0.04 2.68x10
-5
 1108 
Recipient sex -0.01 0.01 1 1196 -0.03 0.01 0.44 1399 -0.20 0.94 1 937 
Sirolimus -0.09 0.03 0.14 1407 -0.03 0.04 1 1399 5.64 2.86 0.96 1108 
Site 0.01 0.01 1 1407 0.001 0.02 1 1399 -2.92 1.15 0.22 1108 
Tacrolimus -0.01 0.02 1 1196 -0.02 0.02 1 1399 -2.25 1.82 1 1108 
Total MM 0.00 0.00 1 1407 -0.003 0.005 1 1196 -0.27 0.36 1 1108 
Table 2. Linear regression results for clinical variables associated with eGFR at 1 year, 5 years and ∆ eGFR from 1 to 5 years 
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Table 3. Most significantly associated polygenic risk scores with eGFR post-transplant 
Meta-analysis results for linear regression of polygenic risk scores vs. eGFR measures. 1/5 year = log10 
eGFR at 1/5 year post-transplant. ∆ = change in eGFR between 1 and 5 years post-transplant. Model was 
adjusted for all available significant clinical covariates and the first eight principal components at each 
site (see section 2.5 and 3.1). D/R = indicates whether the test was carried out on the recipient, donor or 
combined donor-recipient genotype. pT = p-value threshold of the calculated polygenic risk score. 
Estimate = estimated effect size. SE = standard error of the estimate. Pun = uncorrected p-value. 
Padj=approximate adjusted p-value. I² = the proportion of total variation in study estimates that is due to 
heterogeneity. N = number of individuals tested. N SNPs = number of SNPs at the given p-value threshold 
(prior to pruning for linkage disequilibrium). 
 
 
 
  
  
D/R pT eGFR Estimate SE Pun Padj I
2
 N N SNPs 
combined 0.0001 1year 0.011 0.003 4.35x10
-5
 0.001 0.0% 3234 6229 
recipient 0.0001 1year 0.008 0.002 8.68x10
-5
 0.005 6.2% 5295 6229 
donor 0.0001 1year 0.006 0.003 0.01 0.755 2.7% 
3564 
6229 
donor 0.1 5year 0.011 0.005 0.05 1 35.0% 2152 287016 
recipient 0.0001 5year 0.008 0.004 0.06 1 0.0% 2494 6229 
combined 0.0001 5year 0.008 0.005 0.11 1 0.0% 1930 6229 
recipient 0.0001 ∆ 0.668 0.367 0.07 1 0.0% 2191 6229 
donor 0.001 ∆ -0.348 0.358 0.33 1 0.0% 1904 14097 
combined 0.001 ∆ -0.513 0.413 0.21 1 0.0% 1722 14097 
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